Last Week s Revenue Downgrade Sends Genaissance Stock Sliding 7.5 Percent

Oct 25, 2004

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Genaissance Pharmaceuticals slid more than 7 percent this afternoon as investors continued to punish the company for saying it planned to miss year-end revenue expectations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Fluidigm, Ascendas Genomics Ink MDx Development Pact in China
Cancer Dependency Maps Developed by Two Research Teams
Error-Prone DNA Repair Implicated in Analysis of Cancer Mutation Signature Clusters
Ancient Genome Sequences Point to Canaanite Ancestry in Present-Day Lebanese Population
Qiagen Q2 Revenues Grow 4 Percent; Firm Nudges Up Full-Year Guidance
Biomatrica Gets CE-IVD Marks for Sample Collection Tubes

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.

Main menu